John Cox

President and Chief Executive Officer

Waltham, United States

John Cox is the President and CEO of Dyne Therapeutics, bringing extensive executive experience in the biotechnology industry, particularly in rare disease commercialization. Previously, he served as CEO of Bioverativ Inc., where he led the company to $1.1 billion in global sales before its acquisition by Sanofi. He also held senior roles at Biogen and was CEO of Repertoire Immune Medicines. John holds an MBA from the University of Michigan, an M.S. in cell biology from California State University, and a B.S. in biology from Arizona State University.

Expertise

• Leadership
• Strategy
• Operations
• Biotechnology
• Rare Diseases